Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10011633 IBAT inhibitors for the treatment of liver diseases

Patent 10011633 was granted and assigned to Albireo AB on July, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

July 3, 2018

Patent Application Number

15726071

Date Filed

October 5, 2017

Patent Citations Received

US Patent 11583539 Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors

US Patent 11306064 Benzothia(di)azepine compounds and their use as bile acid modulators

US Patent 11603359 Benzothiadiazepine compounds and their use as bile acid modulators

US Patent 11801226 Pharmaceutical formulation of odevixibat

US Patent 11773071 Benzothiazepine compounds and their use as bile acid modulators

US Patent 10941127 Benzothiadiazepine compounds and their use as bile acid modulators

US Patent 10975045 Benzothiazepine compounds and their use as bile acid modulators

US Patent 10981952 IBAT inhibitors for the treatment of liver diseases

Patent Primary Examiner

Patent abstract

The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10011633 IBAT inhibitors for the treatment of liver diseases

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool